Cargando…

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment

Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Song Y, Green, Austin R, Hadi, Rouba, Doolittle-Amieva, Coley, Gardner, Jennifer, Moshiri, Ata S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621191/ https://www.ncbi.nlm.nih.gov/pubmed/36307152 http://dx.doi.org/10.1136/jitc-2022-005257

Ejemplares similares

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022)

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
por: Rizzo, Jason M., et al.
Publicado: (2018)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
por: Orloff, Marlana
Publicado: (2016)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
por: Shmuylovich, Leonid, et al.
Publicado: (2022)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
por: Kaufman, Howard L., et al.
Publicado: (2022)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
por: Quinn, Casey, et al.
Publicado: (2016)

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
por: Perez, Matthew C, et al.
Publicado: (2019)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
por: Lebhar, Jamie, et al.
Publicado: (2023)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
por: Zhang, Tiantian, et al.
Publicado: (2023)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
por: Sun, James, et al.
Publicado: (2020)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
por: Beekman, Kate E., et al.
Publicado: (2023)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
por: Fröhlich, Anne, et al.
Publicado: (2020)

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
por: Mulder, Evalyn E.A.P., et al.
Publicado: (2022)

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
por: Chesney, Jason A., et al.
Publicado: (2023)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
por: Sun, Lillian, et al.
Publicado: (2018)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
por: Ressler, J., et al.
Publicado: (2019)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
por: Blackmon, Jonathan T., et al.
Publicado: (2017)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Kai, Megumi, et al.
Publicado: (2021)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
por: Kaufman, Howard L., et al.
Publicado: (2016)

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
por: Chesney, Jason, et al.
Publicado: (2018)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
por: Kleemann, Johannes, et al.
Publicado: (2021)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
por: Miller, Max, et al.
Publicado: (2023)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
por: Miller, David M., et al.
Publicado: (2018)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_db55jhcju84695fus9q50u6e8c